The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age
作者: Jennifer J. HuangJames J. Hsieh
作者单位: 1Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO
刊名: Seminars in Nephrology, 2020, Vol.40 (1), pp.28-41
来源数据库: Elsevier Journal
DOI: 10.1016/j.semnephrol.2019.12.004
关键词: Renal cell carcinomaTargeted therapyImmunotherapyCombination therapy
原始语种摘要: Summary: Oncologic treatments for renal cell carcinoma (RCC) have undergone a major revolution in the past 2 decades, moving away from the pre-2004 Dark Age during which interleukin 2 and interferon-α were the only therapeutic options and induced treatment responses in only 5% to 10% of patients with metastatic disease. The development of anti-angiogenic tyrosine kinase inhibitors against vascular endothelial growth factor receptor 2 and inhibitors of mammalian target of rapamycin complex 1 in 2005 introduced the Modern Age with better overall and progression-free survival and a greater number of patients (30%-40%) responding to and (∼80%) benefiting from these targeted therapeutic agents. The coming of age of the immuno-oncology era with the use of immune checkpoint inhibitors (ICIs)...
全文获取路径: Elsevier  (合作)
影响因子:2.828 (2012)

  • carcinoma 癌症
  • survival 生存
  • programmed 制订计划了的编制程序了的按程序工作的
  • therapeutic 治疗的
  • protein 蛋白质
  • metastatic 新陈代谢的
  • targeted 对准目标的
  • combined 组合
  • interferon 干扰素
  • circumstance 情况